CTNM Stock Analysis: Buy, Sell, or Hold?
CTNM - Contineum Therapeutics, Inc. Class A Common Stock
$14.21
0.06 (0.42%)
▲
5d:
-2.87%
30d:
+7.25%
90d:
-4.5%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
CTNM is down 3.8% this week, but smart money is accumulating calls. Top strike: $17.5 2026-06-18 with 112 OI. Call ratio: 98% View Scanner →
Strength: 6.7/10
Get Alerted When CTNM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CTNM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CTNM is currently trading at $14.21, which is considered extended relative to its 30-day fair value range of $12.61 to $14.06.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $12.69, while resistance sits at $15.66.
Market Sentiment: CTNM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+54.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CTNM is in a strong uptrend. Immediate support is located at $12.69, while resistance sits at $15.66.
Market Sentiment: CTNM has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $22.00 (+54.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.61 -
$14.06
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 54.8% below Wall St target ($22.00)
Trading Range Analysis
30-Day Trading Range
$12.61 -
$14.06
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.56
(11.0%)
Support & Resistance Levels
Support Level
$12.69
Resistance Level
$15.66
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.21
Wall Street Target
$22.00
(+54.8%)
Share & Embed Analysis
Last updated: May 14, 2026 10:17 PM ET
Data refreshes hourly during market hours. Next update: 11:17 PM
Data refreshes hourly during market hours. Next update: 11:17 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTNM showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$26 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 54 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$130 | 52 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$104 | 55 HOLD |
